Our study substantiated baseline EDS as a strong prognostic predictor for the development of FOG in de novo PD patients, independent of the confounding factors of age, sex, disease duration, TD/PIGD classification, MDS-UPDRS I, MDS-UPDRS II, SCOPA-AUT, GDS, STAI, MoCA, MSE-ADL, striatum DAT uptake and CSF Aβ-42. The gene discussed is SLC6A3; the disease is Parkinson disease.